Category Archives: Other

Verdiva Terminates Weekly Oral GLP-1RA Maintenance Study; Two Deaths Linked to Black Market Reta; Zealand Partners with Generate; Ultragenyx Sells Two PRVs; Amgen At-Home Autoinjector MariTide Study; iBio Preclinical Activin E Data; Biomea FIH BMF-650 Data; Caspian Menin Inhibitor Development Strategy

A series of cardiometabolic-related news items has been observed from Verdiva Bio, FDA, Zealand Pharma, Ultragenyx Pharmaceutical, Amgen, iBio, Biomea Fusion, and Caspian Therapeutics/Kura Oncology. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Rona Partners with Roche for ALK7-Targeting Asset; MetaVia Appoints New CMO; SAB-142 FDA Fast Track Designation

Three cardiometabolic-related news items have been observed: Rona Therapeutics entered into a partnership with Roche for an ALK7 asset to treat metabolic diseases (view press release); MetaVia appointed Sarah Browne as its new Chief Medical Officer (view press release); and SAB Bio received FDA Fast Track designation for the development of SAB-142 in Stage 3 T1DM (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Insulet Omnipod Discover Launch; October CHMP Agenda

Two cardiometabolic-related news items have been observed: Insulet launched its Omnipod Discover platform in the US (view press release), and the CHMP agenda for this month’s meeting (October 12-15) has been released (view agenda). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Amgen T2DM Ph3 MariTide H2H vs. Sema Study; Oral VK2735 Ph3 Obesity Program; Ascensia Enters Another CGM Partnership

Three cardiometabolic-related news items have been observed: Amgen registered its Ph3 MARITIME-T2D-3 study evaluating MariTide H2H vs. injectable sema (view CT.gov record); Viking posted its Ph3 SUNRISE obesity program of oral VK2735 (SUNRISE 1 CT.gov record; SUNRISE 2 CT.gov record); and Ascensia entered into a commercial distribution partnership with Sava (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

MiniMed Initiates 16-day CGM Study; FDA Accepts Bayer’s Finerenone Non-T2DM CKD sNDA; Ribo Life Science Submits Ph1 Application for INHBE siRNA Obesity Study in EU

Three cardiometabolic-related news items have been observed: MiniMed has registered a new study of its next-gen extended-wear CGM, called Unity (view CT.gov record); FDA accepted Bayer’s sNDA for finerenone in non-T2DM CKD (view press release); and Suzhou Ribo Life Science submitted a Ph1 CTA in the EU for its INHBE siRNA in obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

EASD 2026 Winners/Not Winners Analysis: Who Came Out on Top… and Who Didn’t?

Following EASD 2026 (Sep 28-Oct 2; Milan, Italy), FENIX has conducted a winners/not winners analysis, assessing which companies gained further momentum from the conference, remained static, or trended in the wrong direction. Spoiler alert: Lilly clearly came out on top, with EloraTZP setting a new efficacy benchmark for what may be achievable with an amylin + incretin combination. However, winning is not a zero-sum game…

This content is for Read Less members only.
Already a member? Log in here

Viking Initiates Oral VK2735 Maintenance Study and the CCO Shares Departure

Two cardiometabolic-related news items have been observed: Viking Therapeutics initiated its Ph1 oral VK2735 maintenance study (view press release), and Viking’s CCO announced his departure via LinkedIn (view post). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

New Ph3b Survodutide Studies; Regeneron Ph3 Olatorepatide Obesity Program; Corsera Ph1 Angiotensinogen + PCSK9 Combo Study

Three cardiometabolic-related news items have been observed: Boehringer Ingelheim has registered three new Ph3b survodutide studies (SYNCHRONIZE-HERA; SYNCHRONIZE-START; ELEVATE-LIVER); Regeneron posted its Ph3 olatorepatide obesity program on EudraCT (RISE-1; RISE-2); and Corsera initiated a Ph1 FIH study evaluating its angiotensinogen siRNA alone and in combination with a PCSK9 siRNA (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here